+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Cancer Drugs Market by Therapeutic Class (Chemotherapy, Immunotherapy, Stem Cell Transplant), Indication (Leukemia, Lymphoma, Multiple Myeloma), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Blood Cancer Drugs Market by Therapeutic Class (Chemotherapy, Immunotherapy, Stem Cell Transplant), Indication (Leukemia, Lymphoma, Multiple Myeloma), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Blood Cancer Drugs Market by Therapeutic Class (Chemotherapy, Immunotherapy, Stem Cell Transplant), Indication (Leukemia, Lymphoma, Multiple Myeloma), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010967
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The blood cancer drugs market is transforming rapidly, driven by clinical advancements, regulatory evolution, and market dynamics. Senior executives must understand the industry landscape to anticipate investment opportunities and shape competitive strategies.

Market Snapshot: Blood Cancer Drugs Market

The blood cancer drugs market grew from USD 45.98 billion in 2024 to USD 50.96 billion in 2025. It is expected to continue growing at a CAGR of 10.33%, reaching USD 82.96 billion by 2030. This trajectory reflects escalating global demand, innovative therapy introductions, and adaptive commercial strategies. Companies are navigating complexity arising from treatment innovation, shifting payer expectations, and expanding patient populations, with commercial and policy adaptation at the forefront.

Scope & Segmentation

  • Therapeutic Classes: Chemotherapy, Immunotherapy, Stem Cell Transplant, and Targeted Therapy
  • Indications: Leukemia (Acute Lymphoblastic, Acute Myeloid, Chronic Lymphocytic, Chronic Myeloid), Lymphoma (Hodgkin, Non-Hodgkin), Multiple Myeloma (First Line, Second Line, Third Line and Later), and Myelodysplastic Syndromes
  • Route of Administration: Intravenous, Oral, Subcutaneous
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End Users: Clinics, Home Care, Hospitals
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with detailed country coverage), and Asia-Pacific (extensive major and emerging markets)
  • Key Market Participants: Bristol-Myers Squibb Company, AbbVie Inc., Roche Holding AG, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Amgen Inc., Novartis AG, AstraZeneca plc, Gilead Sciences, Inc., Sanofi S.A.

Key Takeaways for Decision-Makers

  • Adoption of next-generation therapies, such as CAR-T and immune checkpoint inhibitors, is reshaping treatment approaches, promoting personalized medicine in blood cancer care.
  • Patient-centric digital health solutions and workflow automation are streamlining clinical trial operations, contributing to improved adherence and accelerated drug development timelines.
  • Policy and reimbursement trends are emphasizing real-world evidence and economic value, impacting launch strategies and pricing models for new blood cancer therapeutics.
  • Strategic alliances, licensing, and technology partnerships are enabling portfolio diversification and facilitating access to innovative delivery models and diagnostic advancements.
  • Regional market performance is influenced by distinct regulatory landscapes, payer systems, and infrastructure investments, requiring tailored approaches for successful market entry and expansion.

Tariff Impact on Supply Chain and Pricing

The implementation of new United States tariffs on pharmaceutical imports in 2025 has added notable complexity to the blood cancer therapeutics supply chain. Increased import duties on active ingredients and finished drugs are prompting manufacturers to reconsider sourcing strategies and regional manufacturing footprints. Distributors and payers must adapt to cost pressures, making supply chain resilience and adaptive pricing strategies essential for maintaining access and margin stability.

Methodology & Data Sources

This report utilizes a mixed-methods approach, combining in-depth primary interviews with key stakeholders—including oncologists, hematologists, and payer representatives—with systematic reviews of peer-reviewed literature, regulatory filings, and industry databases. Quantitative assessment of clinical outcomes, drug approval timelines, and transaction data is supplemented with expert panel reviews to ensure comprehensive and validated insights.

Why This Report Matters

  • Gain strategic guidance to prioritize investments and forecast market opportunities across therapeutic classes and geographies.
  • Leverage insights into policy, reimbursement, and technology adoption to inform resilient commercial models and long-term growth planning.
  • Benchmark organizational strategies against leading companies responding to dynamic clinical, regulatory, and supply chain trends.

Conclusion

Blood cancer drugs market participants must navigate an evolving landscape where clinical innovation, policy adaptation, and commercial agility determine success. This report equips decision-makers with actionable intelligence to drive sustainable value and effective positioning for future growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of next-generation CAR T-cell therapies addressing relapse in refractory blood cancer patients
5.2. Rising investment in bispecific antibody platforms for targeted dual antigen engagement in leukemias
5.3. Integration of minimal residual disease monitoring with digital biomarkers to personalize treatment regimens
5.4. Advancements in oral BTK inhibitors improving patient adherence and reducing infusion center dependency
5.5. Emergence of biosimilar rituximab alternatives driving cost competition and wider therapy access
5.6. Clinical evaluation of epigenetic modulators targeting histone methyltransferases in multiple myeloma
5.7. Pipeline progression of antibody-drug conjugates with novel linkers for enhanced selectivity in lymphoma
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Blood Cancer Drugs Market, by Therapeutic Class
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.4. Stem Cell Transplant
8.5. Targeted Therapy
9. Blood Cancer Drugs Market, by Indication
9.1. Introduction
9.2. Leukemia
9.2.1. Acute Lymphoblastic Leukemia
9.2.2. Acute Myeloid Leukemia
9.2.3. Chronic Lymphocytic Leukemia
9.2.4. Chronic Myeloid Leukemia
9.3. Lymphoma
9.3.1. Hodgkin Lymphoma
9.3.2. Non-Hodgkin Lymphoma
9.4. Multiple Myeloma
9.4.1. First Line
9.4.2. Second Line
9.4.3. Third Line And Later
9.5. Myelodysplastic Syndromes
10. Blood Cancer Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Blood Cancer Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Blood Cancer Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care
12.4. Hospitals
13. Americas Blood Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Blood Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Blood Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. AbbVie Inc.
16.3.3. Roche Holding AG
16.3.4. Johnson & Johnson
16.3.5. Takeda Pharmaceutical Company Limited
16.3.6. Amgen Inc.
16.3.7. Novartis AG
16.3.8. AstraZeneca plc
16.3.9. Gilead Sciences, Inc.
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BLOOD CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. BLOOD CANCER DRUGS MARKET: RESEARCHAI
FIGURE 26. BLOOD CANCER DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. BLOOD CANCER DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. BLOOD CANCER DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BLOOD CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 113. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 114. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 115. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 118. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 119. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 120. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 121. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 122. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 123. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 132. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 133. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 134. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 135. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 136. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 137. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 138. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 139. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 140. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 141. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 216. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 217. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 218. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 219. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 220. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 221. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 232. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 233. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 234. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 235. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 236. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 237. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 260. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 261. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 264. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 265. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 266. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 267. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 268. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 269. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 276. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 277. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 278. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 279. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 280. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 281. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 282. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 283. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 284. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 285. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. SPAIN BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 316. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. SAUDI ARABIA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 328. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 330. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 331. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 332. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 333. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 334. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 335. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 336. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 337. SOUTH AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Blood Cancer Drugs market report include:
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Novartis AG
  • AstraZeneca plc
  • Gilead Sciences, Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 50.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 82.96 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Oncology Drugs Market by Drug Class (Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents), Route of Administration (Injectable, Oral), Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Oncology Drugs Market by Drug Class (Chemotherapy Agents, Hormonal Therapy Agents, Immunotherapy Agents), Route of Administration (Injectable, Oral), Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Immunotherapy Drugs Market by Therapy Type (Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors), Indication (Blood Cancer, Breast Cancer, Lung Cancer), Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2030 - Product Image

Immunotherapy Drugs Market by Therapy Type (Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors), Indication (Blood Cancer, Breast Cancer, Lung Cancer), Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Blood Cancer Drugs Market Report 2025 - Product Image

Blood Cancer Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi, Carvykti, Kymriah), Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), End-use, Region and Segment Forecasts, 2025-2030 - Product Image

CAR T-cell Therapy Market Size, Share & Trends Analysis Report by Product (Abecma, Breyanzi, Carvykti, Kymriah), Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), End-use, Region and Segment Forecasts, 2025-2030

  • Report
  • 90 Pages
  • Global
From
Blood Cancer Therapeutics - Global Strategic Business Report - Product Image

Blood Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From

About the Blood Cancer Drug Market

The Blood Cancer Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of cancer. Blood cancer drugs are used to treat a variety of blood cancers, including leukemia, lymphoma, and myeloma. These drugs are typically administered intravenously or orally, and may include chemotherapy, targeted therapy, and immunotherapy. Blood cancer drugs are designed to target cancer cells while minimizing damage to healthy cells, and may be used in combination with other treatments. The Blood Cancer Drug market is highly competitive, with a number of large pharmaceutical companies offering a range of treatments. Companies in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Merck. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.